早期18F-FDG PET/CT参数联合EBV DNA载量预测初诊鼻咽癌预后
前瞻性纳入60例初诊鼻咽癌患者,在同步放化疗前及期间行18F-FDG PET/CT并检测血浆EBV DNA载量。TLG下降率≤0.6及治疗期间可检测到EBV DNA是不良治疗反应、无复发生存和总生存的预测因素;基于这些独立预测因素构建的评分系统似乎优于传统TNM分期。
要点
- TLG下降率≤0.6预测不完全缓解(p=0.002)及无复发生存下降(p=0.003)。
- 治疗期间可检测EBV DNA、TLG下降率≤0.6及年龄较大与较差总生存独立相关。
- 评分1分和2/3分患者生存分别较0分差,HR为4.756(p=0.074)和18.973(p=0.001)。
核心结论
- 早期评估同步放化疗反应时,18F-FDG PET衍生参数联合EBV DNA载量可预测初诊鼻咽癌患者的结局。
- 联合中期PET参数与EBV DNA载量能更好地区分不同生存率的亚组。
研究设计与样本
- 前瞻性纳入60例初诊鼻咽癌患者,所有患者在同放化疗前及期间行18F-FDG PET/CT。
- 同期检测血浆EBV DNA载量,分析其与PET/CT衍生参数在治疗期间的变化与治疗反应、无复发生存及总生存的关系。
主要发现
- TLG下降率≤0.6及治疗期间可检测到EBV DNA是不良治疗反应、无复发生存和总生存的预测因素。
- 多因素分析中,TLG下降率≤0.6预测不完全缓解(p=0.002)及无复发生存下降(p=0.003)。
- TLG下降率>0.6的患者中达到完全缓解的比例是TLG下降率≤0.6患者的两倍以上。
- 可检测EBV DNA、TLG下降率≤0.6及年龄较大分别与较差总生存独立相关(p=0.037、0.009和0.016)。
- 基于总生存独立预测因素构建评分系统,评分1分和2/3分患者生存分别较0分差(HR 4.756,p=0.074;HR 18.973,p=0.001)。
关键数值与推荐
- TLG下降率≤0.6预测不完全缓解的p=0.002,预测无复发生存下降的p=0.003。
- 可检测EBV DNA预测总生存的p=0.037,TLG下降率≤0.6预测总生存的p=0.009,年龄较大预测总生存的p=0.016。
- 评分系统区分生存的p<0.001,传统TNM分期的p=0.175。
临床怎么用
- 原文结论认为早期联合18F-FDG PET衍生参数与EBV DNA载量评估同步放化疗反应可预测初诊鼻咽癌结局。
- 原文结论认为联合中期PET参数与EBV DNA载量能更好地区分不同生存率的亚组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the value of early evaluation of response to concurrent chemoradiotherapy (CCRT) using 18F-FDG PET-derived parameters and the Epstein-Barr virus (EBV) DNA titre in outcome prediction in patients with primary nasopharyngeal carcinoma (NPC). METHODS: Sixty patients with primary NPC were prospectively enrolled. All patients underwent 18F-FDG PET/CT before and during CCRT. The plasma EBV DNA titre was measured along with the PET/CT-derived parameters. Changes in EBV DNA titre and PET/CT-derived parameters during CCRT were analysed in relation to response to treatment, recurrence-free survival (RFS) and overall survival (OS). RESULTS: A total lesion glycolysis (TLG) reduction ratio of ≤0.6 and a detectable EBV DNA titre during CCRT were predictors of an unfavourable response to treatment, RFS and OS. In multivariate analysis, a TLG reduction ratio of ≤0.6 predicted incomplete remission (p = 0.002) and decreased RFS (p = 0.003). The proportion of patients with a TLG reduction ratio of >0.6 who achieved a complete response was more than twice that of patients with a TLG reduction ratio of ≤0.6. A detectable EBV DNA titre, a TLG reduction ratio of ≤0.6 and older age were independently associated with a poorer OS (p = 0.037, 0.009 and 0.016, respectively). A scoring system was developed based on these independent predictors of OS. Patients with a score of 1 and 2/3 had poorer survival outcomes than those with a score of 0 (hazard ratio 4.756, p = 0.074, and hazard ratio 18.973, p = 0.001, respectively). This scoring system appeared to be superior to the traditional TNM staging system (p < 0.001 versus p = 0.175). CONCLUSION: Early evaluation of response to CCRT using 18F-FDG PET-derived parameters and the EBV DNA titre can predict outcome in patients with primary NPC. A combination of interim PET parameters and the EBV DNA titre enables better stratification of patients into subgroups with different survival rates.
引用
- Chen YH, Chang KP, Chu SC, et al. Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 30264225. doi:10.1007/s00259-018-4172-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。